Kazuhiko Shibata

ORCID

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 2

Top Venues

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, Tomonori Makiguchi, Megumi Inaba, Takeshi Honda, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Yasushi Fukuda, Masayuki Yasugi, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. Therapeutic advances in medical oncology 14 (2022)
Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, Tomonori Makiguchi, Megumi Inaba, Takeshi Honda, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Yasushi Fukuda, Masayuki Yasugi, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. Therapeutic advances in medical oncology 14 (2022)

Kazuhiko Shibata.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kazuhiko Shibata